ÐÂÎÅ×ÊѶ
ÆƾÖÌÇÄò²¡Éö²¡£¡Z6ÈËÉú¾ÍÊDz©MCR»·ëÄÁÆ·¨ÁÙ´²Ç°ÁÆЧÏÔÖø
ÈÕÆÚ£º
2026Äê06ÔÂ15ÈÕ 15:43
ÌÇÄò²¡Éö²¡ÊÇʲô£¿
ÌÇÄò²¡Éö²¡£¨diabetic nephropathy £¬DN£©ÊÇÌÇÄò²¡×îÑÏÖغÍ×î³£¼ûµÄ΢Ѫ¹Ü²¢·¢Ö¢Ö®Ò» £¬ÔÚҽѧÉÏÒ²³ÆΪÌÇÄò²¡ÉöСÇòÓ²»¯Ö¢¡£ËüÊÇÂýÐÔÉöÔಡ£¨chronic kidney disease £¬CKD£©ºÍÖÕÄ©ÆÚÉöÔಡ£¨end stage renal disease, ESRD£©µÄÊ×Òª²¡Òò1¡£Ä¿Ç° £¬ÔÚÎÒ¹úÄËÖÁÈ«ÇòÌÇÄò²¡Éö²¡·¢²¡Âʾù³ÊÉÏÉýÇ÷ÊÆ¡£
ÌÇÄò²¡Éö²¡ÊÇÓÉÓÚ³¤ÆÚ¸ßѪÌÇ״̬µ¼ÖÂÉöÔà½á¹¹ºÍ¹¦ÄÜÖð½¥ÊÜËðµÄ²¡Àí¹ý³Ì¡£»¼Õß»úÌå´æÔÚ¼«Æ临ÔӵĴúлÎÉÂÒ £¬Ò»µ©·¢Õ¹µ½ÖÕÄ©½×¶Î £¬ÍùÍù±ÈÆäËûÉöÔ༲²¡ÖÎÁƸü¼Ó¼¬ÊÖ¡£ÌÇÄò²¡Éö²¡ÔçÆÚÌØÕ÷ÐԸıä°üÀ¨ÉöСÇòÂ˹ýÂÊÔö¸ß¡¢ÉöÌå»ýÔö´ó £¬Ëæºó³öÏÖ΢Á¿°×µ°°×Äò £¬¼Ì¶ø·¢Õ¹ÎªÁÙ´²µ°°×Äò¡¢ÉöÏËά»¯ £¬×îÖÕµ¼ÖÂÉö¹¦ÄܽøÐÐÐÔϽµ £¬Ö±ÖÁÖÕÄ©ÆÚÉöË¥½ß1¡£
£¨Í¼Æ¬À´Ô´£ºhttps://www.hjtdsm.com/yiyong/dn£©
¼òÎöÏÖÓÐÁÆ·¨ £¬¿ÉÒÔ·¢ÏÖ £¬È±·¦Äܹ»Ö±½Ó¡¢Ç¿Á¦×è¶ÏÉöÔàÄÚÔÚÑ×Ö¢ºÍÏËά»¯½ø³ÌµÄ¶à°ÐµãÒ©Îï £¬Êǵ±Ç°ÌÇÄò²¡Éö²¡ÖÎÁÆÁìÓò×îÖ÷ÒªµÄÁÙ´²Î´Âú×ãÐèÇó¡£
Z6ÈËÉú¾ÍÊDz©£¨ÒÔϼò³Æ“Z6ÈËÉú¾ÍÊDz©”£©×ÔÖ÷Ñз¢µÄС·Ö×Ó»·ëÄ£¨MCR¶àëÄ£©ÔÚ×Ô·¢ÐÍÌÇÄò²¡Éö²¡Ä£ÐÍСÊó——db/dbСÊóÉÏÈ¡µÃÁËÏÔÖøÁÆЧ £¬Í¨¹ý¶à°ÐµãÐͬÔöЧ £¬ÓÐÍû´øÀ´DNµÄÁÙ´²ÐÂÑ¡Ôñ£¡
MCR»·ëÄÁÆЧÏÔÖø
db/dbСÊóÊÇÑо¿ÔçÆÚÌÇÄò²¡Éö²¡²¡±äµÄ³£ÓÃÄ£ÐÍ £¬ÆäÓÉÓÚ»ùÒòÍ»±äµ¼ÖÂÊÝËØÊÜÌ幦ÄÜȱÏÝ £¬³ýÁË»á³öÏÖ·ÊÅÖ¡¢¸ßѪÌǵÈÖ¢×´ £¬¸ÃÄ£ÐÍСÊóͨ³£»¹ÔÚÉúÃüÔçÆÚ±íÏÖ³öÃ÷ÏÔµÄÉöСÇòËðÉË£¨·Ê´ó¡¢Ï¸°ûÔö¶àºÍÉöСÇòÓ²»¯£© £¬Ëæ×ÅÄêÁäµÄÔö³¤¶ø¼ÓÖØ £¬»¹±íÏÖ³öÖеȳ̶ȵĵ°°×Äò¡£
ÊÔÑé½á¹ûÏÔʾ £¬¾¹ýΪÆÚ8ÖܵÄÖÎÁÆ £¬Óë¿Õ°×¶ÔÕÕ×édb/dbСÊóÏà±È £¬MCR»·ëĸ߼ÁÁ¿×éСÊóµÄÌÇÉöÏà¹ØÖ¸±ê¾ùÓÐÃ÷ÏԵĸÄÉÆ£º
1¡¢ ¶àÌǺÍÌǵ°°×ˮƽ£ºÏÔÖø½µµÍ×éÖ¯ÖжàÌǺÍÌǵ°°×ˮƽ£»ÓëÄ£ÐÍ×éÏà±ÈϽµ·ù¶ÈÔ¼2/3 £¬ÓëGLP-1¶àëÄ×éÁÆЧÏ൱£»
2¡¢ ½ºÔµ°°×ˮƽ£º´ó·ù¶È½µµÍ½ºÔµ°°×ˮƽ£¨Ô¼2/3£© £¬¼õÉÙ½ºÔ³Á»ý £¬ÏÔÖø¸ÄÉÆÉöÔàÏËά»¯³Ì¶È £¬ÓëGLP-1¶àëÄ×éÁÆЧÏ൱£»
3¡¢ Äòµ°°×ˮƽ£ºÖÎÁÆ4Öܽ«Äòµ°°×ˮƽ´Ó»ùÏß½µÖÁÒ»°ë¡£
ͼ1. db/dbСÊóÉöÔಡ±äͼ
G1½¡¿µ¶ÔÕÕ×é/G2Ä£ÐÍ×é/G3»·ëĵͼÁÁ¿×é/ G4»·ëĸ߼ÁÁ¿×é/G5 GLP-1¶àëÄ×é
MCR»·ëÄ£º¶à°ÐµãÐͬÔöЧ
MCR»·ëÄÔÚÌÇÄò²¡Éö²¡ÖбíÏÖ³öµÄ׿ԽÁÆЧ £¬Ô´ÓÚÆä×÷ΪһÖÖÐͬÐÔË«ÊÜÌ弤¶¯¼ÁµÄ¶ÀÌØÉè¼Æ¡£¸Ã·Ö×ÓÀûÓÃÆä¹¹ÏóÔ¼ÊøµÄ»·ëĽṹ £¬ÊµÏÖÁ˶ԺÚƤÖÊËØÊÜÌåÑÇÐÍMC1RºÍMC4RµÄ¸ßÇ׺ÍÁ¦¼°Ñ¡ÔñÐÔ¹²¼¤»î¡£
ÕâÖÖË«ÖØ°ÐÏò×÷ÓÃÒý·¢ÁËÏÔÖøµÄÐͬÔöЧЧӦ £¬¹²Í¬×÷ÓÃÓÚÌÇÄò²¡Éö²¡µÄºËÐIJ¡Àí»·½Ú £¬×îÖÕµ¼Öµ°°×Äò¼õÇá¡¢×ãϸ°û±£»¤¼°ÉöСÇòÂ˹ý¹¦ÄܸÄÉƵȶàά¶È²¡ÀíÖ¸±êµÄÏÔÖøÄæת £¬Õ¹ÏÖÁ˶à°Ðµã¸ÉÔ¤²ßÂÔÔÚ¸´ÔÓ´úлÐÔ¼²²¡ÖÎÁÆÖеÄÍ»³öÓÅÊÆ¡£
¼¤»îMC1R£ºÃâÒßµ÷½Ú¿¹Ñ×+ÒÖÖÆÏËά»¯½ø³Ì+Ö±½Ó±£»¤×ãϸ°û
MC1RÖ÷Òª´æÔÚÓÚƤ·ôÉ«ËØϸ°û¡¢ÃâÒßϸ°ûºÍÉöÔàϸ°û£¨°üÀ¨×ãϸ°ûºÍϵĤϸ°û£©¡£Í¨¹ý¼¤»îMC1R £¬ÏÔÖøÒÖÖÆNF-κBµÄ»î»¯ £¬¼õÉÙһϵÁдÙÑ×ϸ°ûÒò×Ó£¨TNF-α¡¢IL-6µÈ£©µÄ²úÉú2 3£»Í¬Ê±´Ù½ø¿¹Ñ×Òò×Ó£¨ÈçIL-10£©µÄÊÍ·Å2 3 £¬µ÷½ÚÃâÒßϸ°û £¬¸ÄÉÆÌåÄÚÑ×֢΢»·¾³ £¬Å¤×ªÉöÔà´ÙÑ×״̬¡£
ÉöÔàÏËά»¯£¨Ó²»¯£©Êǵ¼Ö¹¦ÄÜɥʧµÄ×îºóͨ·¡£ÓÐÑо¿±íÃ÷ £¬ºÚƤÖÊËؼ¤¶¯¼Á±»Ö¤Êµ¿ÉÒÔÞ׿¹´ÙÏËά»¯Òò×Ó£¨ÈçTGF-⣩ £¬´Ó¶ø¼õÉÙ½ºÔµ°°×µÈϸ°ûÍâ»ùÖÊµÄºÏ³É £¬ÑÓ»ºÉöСÇòÓ²»¯ºÍ¼äÖÊÏËά»¯µÄ½ø³Ì4¡£
×ãϸ°ûÊǹ¹³ÉÉöÔàÂ˹ýÆÁÕϵĹؼüϸ°û £¬ÆäËðÉ˺ÍÍÑÂäÊǵ°°×ÄòµÄÖ÷ÒªÔÒò¡£Ò»Ð©Ñо¿Ö¸³ö £¬ºÚƤÖÊËؼ¤¶¯¼ÁÄÜͨ¹ýÖ±½Ó×÷ÓÃÓÚ×ãϸ°ûÉϵÄÊÜÌ壨ÈçMC1R£© £¬Îȶ¨Æäϸ°û¹Ç¼Ü £¬ÒÖÖƵòÍö £¬´Ó¶ø´Ó½á¹¹ÉÏά»¤Â˹ý¹¦ÄܵÄÍêÕûÐÔ £¬¼õÉÙµ°°×Äò5 6¡£
ͼ2. MCRÔÚÉöÔàϸ°ûÖеķֲ¼5
¼¤»îMC4R£º¸ÄÉÆÒȵºËصֿ¹ºÍ´úл
MC4RÖ÷Òª´æÔÚÓÚÖÐÊàÉñ¾ÏµÍ³ £¬²ÎÓëµ÷½ÚÄÜÁ¿Æ½ºâºÍʳÓû¡£Í¨¹ý¼¤»îMC4R £¬¸ÄÉÆÈ«ÉíÒȵºËØÃô¸ÐÐÔºÍÆÏÌÑÌÇ´úл £¬ÓÐÀûÓÚ´Ó¸ùÔ´ÉÏÖÎÁÆÌÇÄò²¡Éö²¡——ÌÇÄò²¡¡£
MCR»·ëÄ£º¶à¼²²¡ÁìÓòDZÔÚÓ¦ÓÿÉÄÜÐÔ
Õ¹ÍûδÀ´ £¬Z6ÈËÉú¾ÍÊDz©½«ÒÔMCR»·ëÄÔÚ¼õÖØ´úлÁìÓòÈ¡µÃµÄÍ»ÆÆΪ»ùʯ £¬Æ¾½èÆä×÷ÓûúÖƵĺËÐÄÓÅÊÆ £¬»ý¼«ÍØÕ¹ÖÐÊàÉñ¾ÏµÍ³£¨CNS£©¼°×ÔÌåÃâÒߣ¨×ÔÃ⣩µÈDZÁ¦¾Þ´óµÄÐÂÊÊÓ¦Ö¢ÁìÓò¡£
Êг¡Ç°¾°ÓëÕ½ÂÔ²¼¾Ö
È«ÇòÌÇÄò²¡Éö²¡ÖÎÁÆÒ©ÎïÊг¡Õý´¦ÓÚ¿ìËÙÔö³¤½×¶Î £¬Ô¼30%-40%µÄÌÇÄò²¡»¼Õ߻ᷢչΪÌÇÄò²¡Éö²¡ £¬»¼Õß»ùÊýÅÓ´ó¡£2024ÄêÈ«ÇòDNÒ©ÎïÊг¡¹æÄ£ÒÑÍ»ÆÆ120ÒÚÃÀÔª £¬Ô¤¼Æ2030Ä꽫³¬¹ý300ÒÚÃÀÔª £¬Ä긴ºÏÔö³¤ÂÊ´ï12.5%7¡£Öйú×÷ΪȫÇòÌÇÄò²¡»¼Õß×î¶àµÄ¹ú¼Ò £¬ÕïÁÆÂʵijÖÐøÌáÉýʹÆä³ÉΪ×î¾ßÔö³¤»îÁ¦µÄÊг¡Ö®Ò»¡£
¾¡¹ÜÏÖÓбê×¼ÁÆ·¨²»¶Ï½ø»¯ £¬µ«ÉÐÎÞÄܹ»ÄæתÏËά»¯½ø³ÌµÄÌØÒìÐÔÒ©Îï¡£MCR»·ëÄ´Ó¿¹Ñס¢¿¹ÏËά»¯¡¢´úлµ÷½ÚÈý´óºËÐÄ»·½Úͬʱ½éÈë £¬ÓëÏÖÓÐÁÆ·¨ÐγÉÁ¼ºÃ»¥²¹ £¬ÓÈÆäÔÚ¿¹ÏËά»¯·½Ãæ¾ß±¸¶ÀÌزîÒ컯ÓÅÊÆ¡£
Ä¿Ç° £¬¹«Ë¾Ñз¢¹ÜÏßÕýÎȲ½Íƽø £¬ºóÐø½«Öص㿪չϵͳµÄÁÙ´²Ç°Ò©Ð§Ó붾ÀíѧÑо¿ £¬Ïà¹ØºËÐÄ»¯ºÏÎïÒÑ»ñµÃרÀûÊÚȨ £¬¹¹½¨Á˼áʵµÄ¼¼Êõ±ÚÀÝ¡£ÔÚ´ËרÀû¼Ó³ÖÏ £¬Z6ÈËÉú¾ÍÊDz©½«È«Á¦¼ÓËÙÕâÒ»²îÒ컯¶àëÄÐÂÒ©µÄÑз¢½ø³Ì £¬Ö¾ÔÚÔçÈÕ½«ÆäÍÆÏòÁÙ´² £¬Ô츣ȫÇò»¼Õß £¬Í¬Ê±ÇÀÕ¼ÕâǧÒÚÀ¶º£Êг¡µÄÕ½ÂԸߵء£
×ÊÁÏÀ´Ô´
1.Öйú¹«ÖÚ½¡¿µÍø£¨2014£© £¬¾ÍÕïÖ¸ÄÏ ³£¼û¼²²¡ ÌÇÄò²¡Éö²¡.http://www.chealth.org.cn/mon/diseases/article/MA144004836.html
2. Wang, W., Guo, D. Y., Lin, Y. J., & Tao, Y. X. (2019). Melanocortin Regulation of Inflammation. Frontiers in endocrinology, 10, 683. https://doi.org/10.3389/fendo.2019.00683
3. Ahmed, T. J., Montero-Melendez, T., Perretti, M., & Pitzalis, C. (2013). Curbing Inflammation through Endogenous Pathways: Focus on Melanocortin Peptides. International journal of inflammation, 2013, 985815. https://doi.org/10.1155/2013/985815
4. ÕŽõ.ºÚƤÖÊËضԾÖÔî½Ú¶ÎÐÔÉöСÇòÓ²»¯Ö¢µÄÖÎÁÆ×÷Óü°»úÖÆÑо¿[D].Ö£ÖÝ´óѧ,2022.DOI:"". http://www.tzsti.com:90/D/Thesis_Y3990408.aspx
5. Chang, M., Chen, B., Shaffner, J., Dworkin, L. D., & Gong, R. (2021). Melanocortin System in Kidney Homeostasis and Disease: Novel Therapeutic Opportunities. Frontiers in physiology, 12, 651236. https://doi.org/10.3389/fphys.2021.651236
6. Luipa Khandker, PhD; Priyanka Dhingra, PhD; John H. Dodd, PhD; Carl Spana, PhD; Paul S. Kayne, PhD. (2023). Melanocortin 1 Receptor (MC1R) Agonist PL8177 Protects Against Podocyte Loss in a Streptozotocin-Induced <br/>Rat Model of Diabetic Nephropathy. 14th Biennial International Podocyte Conference Philadelphia, PA. 2023. https://palatin.com/wp-content/uploads/2023/05/PAL-G23PL8.3015-IPD-2023-Khandker-PL8177-Protects-Against-Podocyte-Loss-Poster-0518-2-OK-TO-PRINT.pdf
7. 2025ÖÁ2030ÌÇÄò²¡Éö²¡ÐÐÒµÔËӪ̬ÊÆÓëͶ×ÊÇ°¾°µ÷²éÑо¿±¨¸æ.https://max.book118.com/html/2025/1022/8123135105010001.shtm
Ïà¹ØÍƼö
ÍøÕ¾½¨É裺ÖÐÆó¶¯Á¦ ̨ÖÝ